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Edited by Jesus AvilaAbstract The activity of protein phosphatase (PP)-2A, which
regulates tau phosphorylation, is compromised in Alzheimer dis-
ease brain. Here we show that the transient transfection of PC12
cells with inhibitor-2 ðIPP2A2 Þ of PP2A causes abnormal hyper-
phosphorylation of tau at Ser396/Ser404 and Ser262/Ser356.
This hyperphosphorylation of tau is observed only when a sub-
cellular shift of IPP2A2 takes place from the nucleus to the cyto-
plasm and is accompanied by cleavage of IPP2A2 into a 20 kDa
fragment. Memantine, an un-competitive inhibitor of N-methyl-
D-aspartate receptors, inhibits this abnormal phosphorylation of
tau and cell death and prevents the IPP2A2 -induced inhibition of
PP2A activity in vitro. These ﬁndings demonstrate novel mecha-
nisms by which IPP2A2 regulates the intracellular activity of PP2A
and phosphorylation of tau, and by which Memantine modulates
PP2A signaling and inhibits neuroﬁbrillary degeneration.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neuroﬁbrillary degeneration of abnormally hyperphospho-
rylated tau is a hallmark of Alzheimer disease (AD) and related
tauopathies [1]. The activity of phosphoseryl/phosphothreonyl
protein phosphatase (PP)-2A, which regulates the phosphory-
lation of tau [2], is compromised in AD brain [3]. Bilateral
injection of calyculin A, a potent inhibitor of both PP2A and
PP1, into rat hippocampi produces tau hyperphosphorylation
and behavioral impairment [4].
The intracellular activity of PP2A is regulated by two endog-
enous proteins called inhibitor-1 ðIPP2A1 Þ and IPP2A2 [5,6]. They
non-competitively inhibit PP2A activity with Ki values in the
nanomolar range [5,6]. Several proteins homologous to IPP2A2
have been described and include human SETa [7,8], PHAP-
II [9] and TAF-1 [10]. TAF-1 in its complete form, like IPP2A2 ,
is mainly a nuclear protein and contains a highly acidic C-ter-
minal region that is involved in chromatin remodeling [10].
The N-terminal region of TAF-1 is responsible for its inhibi-Abbreviations: AD, Alzheimer disease; PP2A, protein phosphatase-2A;
IPP2A2 , inhibitor-2 of PP2A; NMDAR, N-methyl-D-aspartate receptor
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protein, but TAF-1b, which lacks the C-terminal region, is
localized in the cytoplasm and inhibits PP2A activity [12]. In
AD brain, the transcription and expression of IPP2A2 is in-
creased and the inhibitor is translocated from its primary nu-
clear location to the cytoplasm accompanied by a cleavage
of the full-length 39 kDa protein into a 20 kDa N-terminal
fragment in the neurons [13]. Moreover, the IPP2A2 cleavage
activity is increased in the AD brain and it co-localizes both
with PP2A and abnormally hyperphosphorylated tau in the
neuronal cytoplasm [13].
Treatment of AD patients with Memantine (1-amino-3,5-
dimethyladamantane hydrochloride), a low to moderate aﬃn-
ity, un-competitive inhibitor of glutamate gated NMDA
receptor channels, results in functional improvement and
reduction of care dependence [14]. The regulation of PP2A
activity in neurons might, in part, be responsible for the neu-
ron-healthy eﬀects of Memantine. NMDA receptor has been
reported to be in complex with PP2A, and stimulation of this
receptor leads to dissociation of PP2A with subsequent reduc-
tion in PP2A activity [15]. We have recently reported that
Memantine inhibits and reverses abnormal hyperphosphory-
lation and accumulation of tau in organotypic culture of rat
hippocampal slices by reversing okadaic acid-induced inhibi-
tion of PP2A activity [16]. The exact mechanism by which
Memantine modulates PP2A signaling has, however, been
elusive.
Rat adrenal pheochromocytoma (PC12) cells provide a sim-
ple and reproducible model system to study various aspects of
neuron biology and have been used as a reliable system to
study N-methyl-D-aspartate receptor (NMDAR) properties
[17]. Functional properties of NMDARs in PC12 cells are very
similar to those described for recombinantly expressed
NMDAR1A–NMDAR2C heteromers [18]. Employing PC12
cells as a model, the present study demonstrates novel mecha-
nisms by which IPP2A2 modulates PP2A activity and produces
abnormal hyperphosphorylation of tau, and by which Meman-
tine inhibits this pathology by directly aﬀecting IPP2A2 -induced
inhibition of PP2A in the cell.2. Materials and methods
2.1. Subcloning and generation of human IPP2A2
IPP2A2 was originally cloned from human brain cDNA using oligonu-
cleotide primers designed to the sequence of human kidney IPP2A2
cDNA as described [19]. The IPP2A2 sequence was ampliﬁed and sub-
cloned into pCI-neo Mammalian Expression Vector (Promega, Madi-
son, WI).blished by Elsevier B.V. All rights reserved.
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We used PC12 cells stably transfected with tau441 [20]. Cell culture
and transfection was done as described previously [19]. Memantine
(Sigma, St. Louis, MO), where applicable, was added to the culture
medium at 6 h post-transfection.
2.3. Western blots and immunocytochemistry
Western blots, immunocytochemical staining and confocal micros-
copy were carried out as described previously [19].
2.4. Inhibition of IPP2A2 activity by Memantine
The in vitro inhibition of PP2A by IPP2A2 and its reversal by Meman-
tine were carried out by ELISA in which dephosphorylation of a tau
phosphopeptide (h tau 194–207-KKK in which Ser 199 is phosphory-
lated) by bovine brain PP2A and its inhibition by recombinant human
brain IPP2A2 in the presence or absence of 100 nMMemantine was deter-
mined.
2.5. Cell toxicity assay
The eﬀect of overexpression of IPP2A2 on the viability of PC12 cells
was determined by assaying the LDH release using CytoTox-ONE
Assay Kit (Promega).
2.6. Statistical analysis
Mean values and S.D.s were computed for each group and analyzed
by Student’s t test. Diﬀerences with P < 0.05 were considered signiﬁ-
cant.Fig. 1. Sub-cellular localization of IPP2A2 in PC12 cells stably expressing
human tau441 after transient transfection with human I
PP2A
2 . (a)
Confocal images of cells immunostained with anti-IPP2A2 (R-42187) at
diﬀerent time intervals following transfection with IPP2A2 . At 48 h post-
transfection, majority of IPP2A2 was seen in the nucleus. By 72–96 h,
most of the inhibitor was observed in the cytoplasm with a few cells
showing nuclear staining (arrow heads). Scale bar: 50 lm. (b) Time
course of IPP2A2 expression in PC12 cells. The expression of I
PP2A
2 was
determined by quantitative chemiluminescent (ECL) Western blots
and data normalized to the values obtained from mock transfected
cells. Data expressed as means ± S.D. Comparison was done between
mock (pcDNA) transfected and IPP2A2 transfected cells.
*P < 0.5,
**P < 0.01.3. Results
3.1. Sub-cellular localization of IPP2A2
Tau441 stably transfected PC12 cells were transiently trans-
fected with human IPP2A2 and immunocytological localization
was studied at 6, 24, 48, 72 and 96 h post-transfection and
using IPP2A2 polyclonal antibody R-42187. Analysis with laser
confocal microscopy revealed detectable endogenous levels of
IPP2A2 in non-transfected cells, and a robust expression of the
inhibitor above endogenous levels by 48 h post-transfection
(Fig. 1a). In most of the cells, the inhibitor was located in
the nucleus at this time point. By 72 h, majority of the transfec-
ted cells showed cytoplasmic localization whereas a few cells
with nuclear staining of the inhibitor could still be seen (arrow-
heads in Fig. 1a). By 96 h, most of the cells showed cytoplas-
mic staining of the inhibitor. The expression of IPP2A2 was the
highest by 48 h but even by 96 h it was 2-fold more than
the mock expression level as quantitated by Western blot anal-
ysis of cell lysates at various time points post-transient trans-
fection (Fig. 1b).
3.2. IPP2A2 induced hyperphosphorylation of tau
We next investigated the eﬀect of IPP2A2 transfection on the
biological correlates of PP2A activity. PP2A is a key enzyme
in regulating the phosphorylation of tau at various phosphor-
ylation sites including pS262 and pS396 [2]. We used hyper-
phosphorylation of tau as an indicator of depressed PP2A
activity in the IPP2A2 transfected cells. Since expression of an
exogenous gene generally peaks by 48 h post-transient transfec-
tion, we prepared cell lysates at 48-h time point to analyze the
cells for tau hyperphosphorylation by Western blots. We found
no detectable diﬀerences in the phosphorylation levels of tau at
either PHF-1 or 12E8 sites at 48 h post-transfection (data not
shown). This lead us to speculate that since IPP2A2 was mainly
localized in the nucleus at 48 h (Fig. 1a), while PP2A is a cyto-
solic protein, IPP2A2 was probably unable to inhibit PP2A activ-ity due to spatial constraints. We therefore, carried out
immunocytochemical analysis of the cells at both 48 and 96-h
post-transfection. Consistent with the above scenario, confocal
microscopic images of cultured cells at 48 h showed minimal, if
any, hyperphosphorylation of tau at PHF-1 or 12E8 sites.
However, at 96 h, a time when majority of the inhibitor was
localized in the cytoplasm, we could observe a sharp increase
in PHF-1 and 12E8 immunostaining (Fig. 2a and b).
3.3. Inhibition of hyperphosphorylation of tau by Memantine
We have previously shown that Memantine inhibits and re-
verses PP2A-inhibition-induced abnormal hyperphosphoryla-
tion of tau in organotypic rat hippocampal slice cultures
[16]. However, the exact mechanism by which Memantine re-
stored PP2A activity was not known. Since IPP2A2 is one of
the two naturally occurring modulators of PP2A signaling in
cells, we postulated that Memantine might regulate IPP2A2
Fig. 2. Hyperphosphorylation of tau in PC12 cells stably expressing
human tau441 after transient transfection with human I
PP2A
2 . Tau441-
PC12 cells were transiently transfected with human IPP2A2 , ﬁxed at 48 or
96 h post-transfection and double labeled with anti-IPP2A2 , R-42187
(red) and either anti-phospho-tau (green) PHF-1 [against pS396/pS404
in (a)] or 12E8 [against pS262/pS356 in (b)] for analysis by confocal
microscopy. Expression of IPP2A2 caused robust phosphorylation of tau
at both PHF1 (a) and 12E8 (b) sites when the inhibitor was located in
the cytoplasm (96 h), whereas minimal eﬀect was observed when the
inhibitor was localized in the nucleus (48 h).
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the eﬀect of Memantine on the IPP2A2 -induced tau hyperphosph-
orylation. PC12 cells were treated with 10 lM Memantine at
6 h post-transfection with IPP2A2 for a total of 90 h. Cells were
ﬁxed for immunocytochemistry at 96 h post-transfection.
Immunocytochemically, Memantine clearly inhibited the
abnormal phosphorylation of tau at PHF1 and 12E8 sites in
treated PC12 cells (Fig. 3a). Western blot analysis of cell ly-
sates was performed next using polyclonal antibody against
IPP2A2 (R1482). Cells were separated according to their attach-
ment to the culture plates at the time of harvest. Floating cells,plus cells that came oﬀ the culture plate during PBS wash,
comprised a population in which the percentage of IPP2A2 trans-
fected cells or cells expressing higher amounts of the inhibitor
was greater than that in the attached population (Fig. 3b and
d). While as much as 30–40% of the IPP2A2 transfected cells de-
tached, there was no signiﬁcant cell detachment in the various
control experiments to warrant separate analysis. For bio-
chemical studies, the detached cells were analyzed separately
from the attached cells. Western blots showed an increase in
phosphorylation of tau at PHF1 and 12E8 sites in detached
cells. Memantine restored the phosphorylation levels of both
PHF1 and 12E8 sites to control levels (Fig. 3b and c). Immu-
nocytochemical staining was not carried out on detached cells,
but images were selected from the attached cells to show proof
of the principle. Tau hyperphosphorylation, though detectable
immunocytochemically, could not be observed biochemically
in the attached cells.
TAF-1, which is homologous to IPP2A2 , has been implicated in
chromatin remodeling [10,21] and was identiﬁed as a stimula-
tory factor for replication and transcription when adenovirus
DNA complexed with basic viral core proteins was used as a
template for cell-free systems [22,23]. In order to conﬁrm that
the reversal of IPP2A2 induced tau hyperphosphorylation by
Memantine was not due to the regulation of IPP2A2 expression
in transfected cells, we compared the inhibitor levels in cell ly-
sates obtained from both Memantine untreated and treated
cells. Quantitative analysis failed to reveal any eﬀect of
Memantine on IPP2A2 protein levels (Fig. 3d). Thus, the eﬀect
of Memantine in restoring phosphorylation status of tau was
not apparently due to the modulation of IPP2A2 expression.
Since transfection with IPP2A2 caused an increase in cell detach-
ment, and detached cells comprised of a population of cells with
a higher percentage of IPP2A2 immunoreactivity (Fig. 3d), we next
sought out to see the level of cytotoxicity in these cells by Cyto-
tox-1 assay. As expected, transfection with IPP2A2 caused a36%
increase in cytotoxicity at 48 h post-transfection. This was re-
duced to 13% after Memantine (10 lM) was added to the cul-
ture medium at 6 h post-transfection and maintained till
analysis (Fig. 3e). Treatment of mock transfected cells with
Memantine as a control also caused an unexpected small in-
crease in cytotoxicity. The molecular events linking IPP2A2 over-
expression and cell death in these cells remain to be investigated.
We had previously speculated that a selective cleavage and
translocation of IPP2A2 from its primary nuclear localization
to the cytoplasm in cortical neurons undergoing neuroﬁbrillary
degeneration in AD might represent a novel mechanism by
which IPP2A2 inhibits PP2A activity, and leads to abnormal
hyperphosphorylation of tau [13]. In the present study, immu-
nocytochemical data showed an increase in phosphorylation of
tau at PHF1 and 12E8 sites at 96 h post-transfection, and since
this also represented a time point when IPP2A2 was mainly local-
ized in the cytoplasm, we investigated whether the hyper-
phosphorylation of tau observed in the 96 h transfected cells
was associated, at least in part, with a selective cleavage of
IPP2A2 in the these cells. Western blot analysis indeed, showed
the presence of a 20-kDa cleavage product of IPP2A2 in the de-
tached cell population harvested at 96 h post-transfection
(Fig. 4). We could also observe the presence of two other
IPP2A2 cleavage fragments of 25 kDa and 28 kDa. These
additional cleavage fragments were previously reported [13].
The detachment of transfected cells from the culture wells
was associated both with increased level of expression of
Fig. 3. Eﬀect of Memantine on IPP2A2 induced hyperphosphorylation of Tau at PHF1 and 12E8 sites in PC12 cells stably expressing human tau441.
Tau441-PC12 cells were treated in the presence (+) or absence () of 10 lM Memantine at 6 h post-transfection with human IPP2A2 . (a) At 96 h post-
transfection, cells were ﬁxed and double stained with anti-IPP2A2 (R-42187, red) and anti phospho-tau (green) PHF1 (upper 2 panels) or 12E8 (bottom
2 panels). Images were obtained by laser confocal microscopy. Memantine reduced phosphorylation of tau at both sites. A similar experiment was
run side by side and treated identically as in (a) except that cells that were detached from the culture plate at the time of harvest were separated from
the attached cells for Western blot analysis (b) and quantitation (c). Transfection with human IPP2A2 caused hyperphosphorylation of tau at PHF1 and
12E8 sites (27% and 36%, respectively), which was reversed by 10 lMMemantine treatment in detached cells. (d) The level of IPP2A2 in detached cells
was greater than in attached cells. Memantine had no eﬀect on the levels of IPP2A2 . Results represent up to six independent experiments. Antibodies
used were mAb PHF1 (against pS396/pS404), mAb 12E8 (against pS262/pS356), 134d (total tau) and mAb 10E7 (full length IPP2A2 ). (e) I
PP2A
2 induced
cytotoxicity in PC12 cells stably expressing human tau441. Cytotox-1 assay was used to quantify cytotoxic eﬀects of I
PP2A
2 transfection on PC12 cells.
Transfection with human IPP2A2 caused 36% increase in cytotoxicity which was decreased to 13% after 10 lM Memantine treatment. Results are
presented as means ± S.D. *P < 0.05, **P < 0.01.
Fig. 4. Eﬀect of Memantine on the cleavage of IPP2A2 at 96 h post-
transfection. PC12 cell lysates were prepared after 96 h of transfection
with human IPP2A2 . Cell lysates were separated based on their
attachment to the culture plates at the time of harvest and analyzed
by Western blots developed with polyclonal antibody R1482 against
IPP2A2 . Lanes 4–7 show expression of full length I
PP2A
2 (arrow). Lanes 5
and 7 show a 20 kDa fragment of IPP2A2 (arrowhead) which was
observed in cell lysates prepared from detached cells in the respective
treatment groups. Small arrows indicate 25 kDa and 28 kDa amino
terminal fragments of IPP2A2 also reported previously (see Section 3).
Con (control), Mck (mock treated), M/Mem (mock with 10 lM
Memantine), Inh.Tx (cells transfected with IPP2A2 alone), Inh.Tx/Mem
(cells transfected with IPP2A2 and treated with 10 lM Memantine), Det
(cells detached from the culture plate) and Att (cells attached to the
culture plate at the time of harvest). Memantine, where indicated, was
added to the culture medium at 6 h post-transfection for a total
treatment time of 90 h.
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cleavage probably contributed to increase in hyperphosphory-
lation of tau seen selectively in the detached cells. We could not
detect any eﬀect of Memantine on the cleavage of IPP2A2 . Taken
together, Memantine restored the IPP2A2 -induced abnormal
phosphorylation of tau to normal levels, but seemed to have
no eﬀect on the expression, sub-cellular localization or cleav-
age of IPP2A2 . We next entertained the possibility of a direct
interaction of Memantine with IPP2A2 .
3.4. In vitro inhibition of PP2A activity by IPP2A2 and its reversal
by Memantine
Previously, we had demonstrated that Memantine does not
have direct interaction with PP2A [16]. To investigate whether
Memantine directly interacted with IPP2A2 , we examined its ef-
fect on inhibition of PP2A activity by IPP2A2 . I
PP2A
2 inhibited
the PP2A (puriﬁed from bovine brain) catalyzed dephospho-
rylation of the tau peptide at Tau-1 site. At 5 and 25 nM con-
centration, IPP2A2 inhibited 11% and 33% of PP2A activity,
respectively. This eﬀect of IPP2A2 on PP2A activity was inhibited
by 100 nM Memantine (Fig. 5a). Memantine as such had no
eﬀect on PP2A activity (Fig. 5b).4. Discussion
Independent of the etiology, neuroﬁbrillary degeneration of
abnormally hyperphosphorylated tau appears to be required
Fig. 5. In vitro inhibition of PP2A by IPP2A2 and its reversal by Memantine. (a) Recombinant human brain I
PP2A
2 inhibited the PP2A (bovine brain
holoenzyme) catalyzed dephosphorylation of abnormally hyperphosphorylated tau peptide at the Tau-1 site in a dose dependant manner (open bars).
Memantine (100 nM) reversed the IPP2A2 -induced inhibition of PP2A activity (ﬁlled bars). (b) In the absence of I
PP2A
2 , Memantine did not have
any signiﬁcant eﬀect on PP2A activity. Results are presented as means ± S.D. *P < 0.05; E + S, enzyme + substrate; E + S + M, enzyme +
substrate + memantine.
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viously, we have shown that IPP2A2 is both overexpressed and
selectively translocated from neuronal nucleus to cytoplasm
in AD brain [13] and that the activity of PP2A is compromised
by 20% in AD neocortex [3]. The present study demonstrates
that probably the translocation of IPP2A2 from the nucleus to the
cytoplasm and its cleavage into the amino and carboxyl termi-
nal halves are required for the abnormal hyperphosphoryla-
tion of tau. PP2A regulates phosphorylation of tau not only
directly by dephosphorylation of tau but also by regulating
the activities of several tau kinases [16,24–26]. Thus, inhibition
of IPP2A2 oﬀers a promising target for the treatment of AD and
related tauopathies.
We had previously shown that in AD temporal cortex and
hippocampus, but not cerebellum, the transcription and
expression of IPP2A2 are signiﬁcantly increased [13]. Further-
more, IPP2A2 is selectively translocated in neurons from its pri-
mary nuclear localization to the cytoplasm accompanied by
the appearance of a 20 kDa amino terminal cleavage frag-
ment of the full length protein in the cytosol from cortical
and hippocampal brain tissue in AD cases [13]. This 20 kDa
fragment of IPP2A2 , which has been reported by others as well
[8,12], is derived from the cleavage of 39 kDa IPP2A2 /SET/
TAF-1 and has inhibitory activity towards PP2A [12]. More-
over, in HeLa cells transfected with amino terminal half of
TAF1, the inhibitor localized to the cytoplasm [12]. The pres-
ent study shows an increase in hyperphosphorylation of tau at
pSer396/pSer404 and pSer262/pSer356 sites in PC12 cells
transfected with full length IPP2A2 , only at the time when I
PP2A
2
is immunocytochemically observed in the cytoplasm. This in-
crease in the phosphorylation of tau was observed in a popu-
lation of cells with the highest expression of IPP2A2 and the
same cells also showed an increase in 25 kDa and 28 kDa
amino terminal fragments, and the appearance of 20 kDa
cleavage product of IPP2A2 . Exactly what causes the transloca-
tion of IPP2A2 from the nucleus to the cytoplasm and the mech-
anisms of the generation of its N-terminal cleavage fragments
remain to be studied. It is currently unknown whether, along
with the 20 kDa fragment, full length IPP2A2 also translocates
to the cytoplasm. IPP2A2 is known to have several nuclear [12]
and cytoplasmic functions [27]. The presence of a highly acidic
C-terminal region brings about its nuclear retention [12] and
IPP2A2 lacking the C-terminal acidic domain is localized mainly
in the cytoplasm. Protein transport represents a very eﬃcientway to rapidly modify the activity of such proteins by changing
their localization, and involves a group of carrier proteins
called Transportins (Exportins or Importins) [28]. It is very
likely that IPP2A2 has both nuclear localization signal (NLS)
and nuclear export signal (NES) in its sequence. However,
the exact nature of the processes that regulate the intracellular
shift of IPP2A2 remains to be understood. Regarding the genera-
tion of the 20 kDa cleavage fragment of IPP2A2 , we have previ-
ously reported that recombinant human IPP2A2 was digested
faster with AD than control brain extract, generating similar
proteolytic fragments of the inhibitor [13], but the speciﬁc pro-
tease(s) involved in the cleavage is not yet known.
PP2A activity is well known to be critical for cell survival
and is thus, tightly regulated. We found 11% and 33% inhibi-
tion of PP2A activity by 5 nM and 25 nM IPP2A2 in vitro, and a
similar corresponding increase in phosphorylation of tau at
PHF-1 and 12E8 sites. This increase in abnormal hyper-
phosphorylation of tau over a long period of time in AD,
which on average has a progression period of 7–10 years, is
apparently detrimental to the aﬀected neurons.
We have previously reported that Memantine, a moderate
aﬃnity un-competitive inhibitor of NMDA receptors, can re-
verse okadaic acid-induced inhibition of PP2A in organotypic
explant cultures of rat brain hippocampal slices, but the exact
nature of such a rescue of PP2A activity by Memantine was
not known. The present study also, for the ﬁrst time, demon-
strates a possible role of Memantine in modulating PP2A sig-
naling by reversing IPP2A2 induced inhibition of PP2A activity.
We show that Memantine in cultured PC12 cells stably
expressing tau441 was able to inhibit the abnormal hyper-
phosphorylation of tau caused by transient transfection of
the cells with IPP2A2 . Memantine had no eﬀect on expression
of the transgene suggesting that it probably alters the biologi-
cal activity of IPP2A2 directly. Furthermore, we show that
Memantine could disinhibit the IPP2A2 induced-inhibition of
PP2A activity in vitro at therapeutic concentrations [30]. Ta-
ken together, the present study shows that Memantine restores
normal phosphorylation state of tau, probably, by downregu-
lating IPP2A2 ’s ability to inhibit PP2A.
Memantine is a positively charged molecule and in order for
it to inﬂuence PP2A activity it must gain entry into the cell. It
was recently reported that the binding site of Memantine is an
intracellular Mg+ site on the NR-1 subunit of NMDAR [29].
Therefore, it is reasonable to assume that some of the drug
3978 M.O. Chohan et al. / FEBS Letters 580 (2006) 3973–3979probably ﬁnds its way into the cytoplasm where it may interact
with IPP2A2 . Memantine acts as an un-competitive inhibitor of
mostly open-gated NMDAR-associated Ca2+ channels. Under
physiological conditions, the NMDA channel is activated for
only brief periods of time due to relief of Mg2+ blockade. This
contrasts with the situation in chronic neurodegenerative con-
ditions like AD, where there is an overactivation of NMDAR
[30]. In AD, for example, the brain metabolism is decreased
[31] and therefore, the energetically deprived neurons become
depolarized easily due to a failure in maintaining ionic homeo-
stasis. This, in turn, may lead to the unbinding of the positively
charged Mg+ ion from its binding site, leading to the opening
of NMDAR channels (despite the absence of increased gluta-
mate) and inﬂux of Ca+. As more neurons die, the concentra-
tion of glutamate in the extracellular milieu is likely to
increase, leading in turn to a persistent overactivation of
NMDAR. Such an increase in NMDAR activity leads to the
channels being excessively open (for relatively longer periods
of time). It is this excessive opening of the NMDAR channels
which allows Memantine to gain access to the internal Mg2+
binding site. Since AD is a slowly progressive disorder and
the persistent NMDAR hyperactivity sets in probably several
years after the clinical onset of the disease, it is quite logical
to expect any eﬀect of Memantine to occur only in the later
stages of the disease. Although hyperphosphorylation of tau
is an early event in the pathogenesis of AD, in the absence
of NMDAR hyperactivity in early stages of the disease (a state
when the channels are open only brieﬂy and Memantine has
limited chance of getting inside the cell), we would not expect
Memantine to interact with IPP2A2 and inhibit abnormal phos-
phorylation of tau. It is only when continued insults coupled
with ‘‘metabolic-paresis’’ leads to persistent NMDAR hyper-
activity; a common event in the late stages of many chronic
neurodegenerative conditions, that Memantine is able to inﬂu-
ence both the NMDAR as well as IPP2A2 induced inhibition of
PP2A activity, and henceforth, tau hyperphosphorylation. De-
creased levels of hyperphosphorylated tau in the CSF of pa-
tients with moderate to severe AD receiving Memantine
therapy could provide a very useful proof of principle of resto-
ration of PP2A activity as a therapeutic target.
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